What is Neuroblastoma?
Neuroblastoma is a solid tumour childhood cancer with the average age of diagnosis being just 2 years old.
It claims more lives of children under the age of 5 than any other cancer.
The average survival rate for aggressive neuroblastoma is only 50% and the rate for the most aggressive form of neuroblastoma can be as tragically low as 15%. A third of the survivors of neuroblastoma have long term side effects from their actual treatments.
We need to improve treatments so they are more effective and less toxic and the way to do this is through research. Profits from Run2Cure go to neuroblastoma research projects. One research project that Run2Cure has contributed to for the last 4 years is called CBL137 and this is a drug being developed and tested at Children’s Cancer Institute in Randwick. The drug has shown promising results and is planned to go into paediatric clinical trial in Australia and America shortly. Please visit www.neuroblastoma.org.au for more information.
By helping today you will help children diagnosed this year and in the future and lives will be saved.
Neuroblastoma does not need a miracle just more research!
Lowy Research Centre
Research at CCIA
One night, back in July 2015, four and a half year old Amber had woken up from her sleep complaining of a sore stomach – which was very out of ordinary for her as she always sleeps right through the night.
The next day she was still not well and sore in her stomach, so her parents Peter and Sarah decided to take her to their closest hospital to get her checked out. Once there, she was given some medicine and started to feel better however, she still needed to go for further tests to get to the bottom of her concerns.
After getting a scan on her stomach it was made apparent that Amber was very unwell. The radiologist had seen scans like hers before and believed she had the rare childhood cancer, neuroblastoma.
At the John Hunter Hospital in Newcastle, Amber underwent a mass of tests, ultrasounds and surgery with the results confirming Peter and Sarah’s fears – their precious little girl had stage 4 high risk neuroblastoma.
Amber immediately commenced treatment, which consisted of chemotherapy every 10 days for 70 days. Initial tests after this time had showed improvement, however more still needed to be done. Since then Amber has undergone further rounds of chemotherapy, radiation therapy and a stem cell transplant.
Amber has recently relapsed and is having additional treatment.
The research undertaken at Children’s Cancer Institute is the key to uncovering safer, more effective treatments that are absolutely critical to families like Amber’s.